Abstract The primary objective of this study was to examine the association between depression, anxiety symptoms, and glycemic control in Malaysian women with type 2 diabetes mellitus (T2DM). Another objective was to examine the association between glycemic control and mental status, measured by mental composite score (MCS). This study was conducted on 611 randomly sampled Malaysian women with T2DM who were treated as outpatients at medication therapy adherence clinics (MTAC). The Delusions-Symptoms-States Inventory: State of Anxiety and Depression (DSSI/SAD) and Center for Epidemiologic Studies Depression Scale 10 (CES-D 10) were used. Five most recent readings of hemoglobin A1c (HbA1c), fasting, and random glucose levels were recorded. Regression analysis was used to correlate glycemic control with depression, anxiety symptoms, and MCS, while considering potential confounders. For depression symptoms, an increase of one category was associated with a small average HbA1c increase of 0.10 % (95 % CI −0.38, 0.68), whereas for anxiety symptoms, there was a small decrease in average HbA1c of 0.44 % (95 % CI −1.17, 0.28); both were not significant. Very poorly controlled HbA1c was not significantly associated with symptoms of depression (OR 1.43, 95 % CI 0.45-4.55) or anxiety (OR 0.47, 95 % CI 0.15-1.49). MCS was found to have a strong inverse correlation with HbA1c. That is, women who reported poor MCS had a significantly higher, and therefore very poorly controlled, HbA1c (OR 1.70, 95 % CI 1.01-2.88). The presence of depression and anxiety symptoms was not significantly associated with glycemic control in women with T2DM, supporting the hypothesis that argues against the existence of a link between depression, anxiety, and glycemic control.
Introduction
People with diabetes mellitus (DM) experience a number of complications during the course of the disease, including psychological problems. Depression and anxiety are the two most common comorbid conditions associated with DM [1] . Comorbid depression or anxiety together with DM may result in poor metabolic control, higher complication rates, poorer quality of life (QoL), increased management costs, disability, and mortality rates [2] [3] [4] . It has been estimated that depressive disorders are higher among women with or without diabetes than among men; globally, depressive disorders in women were the fourth leading cause of disease burden and the seventh leading cause in men [2] [3] [4] . Studies from developed countries reported higher prevalence of depression in women compared to men [3, 5] . Although not many studies have been conducted in developing countries, a higher prevalence of depression and anxiety symptoms among women has been reported [6, 7] . Women with DM also exhibit poorer diabetes self-care, glycemic control, and QoL than men with DM, which are further exacerbated by depression [8] .
Glycemic control is one of the top priorities in the management of people with DM in order to reduce the macro-and micro-vascular complications [9] . Depression has been found to affect glycemic control as well as macro-vascular and micro-vascular complications [9] [10] [11] , and there is substantial evidence that comorbid depression among individuals with DM is associated with poor DM outcomes such as poor glycemic control [9, 12] .
Significant controversy exists over whether or not depression and anxiety in patients with DM is associated with poorer glycemic control, with some studies reporting moderate to strong associations [10, [13] [14] [15] between depression symptoms and hemoglobin A1c (HbA1c), while others have found no association [16] [17] [18] . Recent studies suggest that anxiety disorders may also be associated with less favorable glycemic control among adults with DM [19] [20] [21] . However, glycemic control as a risk factor was associated only with higher anxiety scores [22] . Prevalence of moderate to severe depression was found to be significantly associated with poor glycemic control in men but not in women [19, 23] , and cross-sectional studies have found a significant positive correlation between depression symptoms and HbA1c in patients with type 1 diabetes but no significant correlation in patients with type 2 diabetes mellitus (T2DM) [24, 25] . The evidence gives rise to the hypothesis that depression and anxiety affect glycemic control in men and those with type 1 DM but not women and patients with T2DM. In order to test this hypothesis in a developing country, we conducted a study to examine the association between depression, anxiety symptoms, and glycemic control in Malaysian women with T2DM.
Methods

Study design and participants
Six hundred and eleven Malaysian women with a known diagnosis of T2DM for at least 1 year, who were treated as outpatients at medication therapy adherence clinics (MTAC) at PutraJaya Hospital in PutraJaya, and Tuanku Jaa'far Hospital and Seremban Health Clinic in Negeri Sembilan, were invited to participate in this study. Face-to-face interviews were conducted at the outpatient clinics, using selfadministered questionnaires. The study was conducted according to the principles expressed in the Declaration of Women were categorized as having T2DM if they were attending MTAC for the management of T2DM. Every second woman with diabetes on the respective patients' list at the clinic sites was invited to participate; verbal or written consent was obtained from participants who met the inclusion criteria. The data were collected on women aged 35 and above. Information was confirmed by accessing patients' medical records. The presence of T2DM was identified according to two criteria: A fasting plasma glucose (FPG) greater than or equal to 7.0 mmol/l and random plasma glucose (RPG) greater than or equal to 11.1 mmol/l. Women diagnosed with T1DM were excluded.
Measurement of depression and anxiety symptoms
Center for Epidemiologic Studies Depression Scale 10 (CES-D 10), a brief self-report screening tool for depressive symptoms derived from the validated 20-item CES-D 20 [26] , was used to assess depression symptoms. It has been shown to have reliability and validity comparable to the standard 20-item CES-D instrument and is considered a good instrument for screening depression in patients with T2DM [27] . The CES-D 10 uses a zero-to-three response scale, with total symptom severity scores ranging from 0 (no depression) to 30 (severe depression) [28] . Participants in this study were categorized as depressed if they scored 11 or more; this is a commonly used cutoff point for CES-D [26] .
The anxiety symptoms were assessed using the DelusionsSymptoms-States Inventory: State of Anxiety and Depression (DSSI/SAD). It contains 14 symptoms, 7 for depression and 7 for anxiety. The DSSI was developed for use with community samples and has been validated against clinical samples with diagnosed mental illness [29] [30] [31] , and was also found to correlate well, and shares items with, other established symptoms scales such as the Edinburgh Postnatal Depression Scale (EPDS) and the Hospital Anxiety/Depression Scale (HADS) [32] . Participants in this study were classified as anxious when they reported four or more symptoms. DSSI/SAD is an instrument used to evaluate anxiety and depression symptoms but has not yet been validated for use among people with diabetes [29] . Therefore, we validated the DSSI instrument. Internal consistency was 0.86 for the anxiety and 0.90 for depression subscales, and 0.93 for the full scale of DSSI/SAD. Principal component analysis revealed a bifactorial model. Correlation analysis showed a significant negative correlation between DSSI-Anxiety and the mental composite score (MCS) scale of Short Form 12 of the Medical Outcomes Study (SF-12; r=−0.404, p=0.001); thus, as anxiety symptoms decreased (DSSI), the MCS increased, indicating lower mental health-related limitations. We found significant variations in the DSSI/SAD domain scores that could be explained by CES-D (DSSI-Anxiety 55 %, DSSI-Depression 46 %) and SF-36 MCS (DSSI-Anxiety 66 %, DSSIDepression 56 %) suggesting that the DSSI/SAD can be used for measuring depression and anxiety symptoms in people with diabetes.
Mental health status by mental composite score (MCS)
We also measured overall mental health functioning using MCS of the SF-12. SF-12 is a multipurpose survey instrument comprising 12 questions, developed as a legitimate alternative to the SF-36. The two summary scales, MCS and the Physical Component Summary (PCS), provide an insight into mental and physical health as well as disability level [33] . MCS examining the impact of health on mental health function was calculated using the method described by Ware et al. [34] . The MCS ranged from 0 to 100; "0" implies poor mental health and "100" implies good mental health. The median split method was used to categorize participants where scores less than the median indicate poor MCS.
Assessment of glycemic control
Five most recent blood glucose readings were collected from patients' medical records. Mean and median values were calculated and used for all comparisons. The monitoring of hemoglobin A1c (HbA1c) is considered the gold standard for glycemic control. The general HbA1c target in people with T2DM is ≤7 %, and adjustment to diabetes treatment should be considered when HbA1c is above this level [35] , although other guidelines suggest 6.5 % or less as the treatment goal, which is closer to the normal healthy value [36] . The HbA1c, fasting blood glucose (FBG), and random blood glucose (RBG) values were used as both continuous and categorical outcomes. We used >7 % HbA1c value as the cutoff point to define poor glycemic control. The HbA1c was also categorized based on quartile values: good controlled, moderately controlled, poorly controlled, and very poorly controlled HbA1c.
For fasting and random blood glucose, we used the National Health and Medical Research Council (NHMRC) classification for people with T2DM, namely normal, moderate, and high levels [37] . A fasting value between 4 and 6 mmol/l was normal, between 6.1 and 6.9 mmol/l was moderate, and anything above 7 mmol/l was high [37] . For non-fasting or random blood glucose, a normal value was between 4 and 7.7 mmol/l, between 7.8 and 10.9 mmol/l was moderate, and anything above 11 mmol/l was high [37] .
Assessment of covariates
Potential confounders and risk factors were identified on the basis of their association with outcomes and a priori knowledge [11, 23, 38] . Socio-demographic information included age, ethnicity, education, occupation, monthly income, alcohol consumption, and cigarette smoking (non-smokers, past smokers, and current smokers). These were collected from participants. Clinical and physical parameters such as comorbidities or medical conditions other than T2DM and height (m) and weight (kg) measurements were obtained from participants' medical records. Body mass index (BMI, kg/m 2 ) was then calculated to categorize participants based on the WHO criteria [39] . For physical health, the Short Form 12 of the Medical Outcomes Study (SF-12) was used, with lower scores indicating poor physical health. The PCS scores were calculated using the scores of the questions, ranging from 0 to 100, with lower scores indicating greater physical limitation [33] . The median split method was used to categorize participants where scores less than median indicate poor PCS. The self-reported information on level of physical activity (not at all, one to two times a week, three or more times a week), and sleep problems (Nil, acute and chronic), were collected from participants.
Statistical analysis
The data were analyzed using the Statistical Package for the Social Sciences (SPSS)® version 20 and Stata IC® version 12, with a significance level of ≤0.05. Descriptive statistics were used to calculate percentages, frequencies, means, and standard deviations. The relationship between variables for categorical data was performed using the χ 2 (Chi-Sq). Fisher exact test was applied in cases where sample size was small. Similarly, on occasions where we had less than five readings per cell for Chi-Sq, likelihood ratio test was applied. Comparisons between groups with normal distribution were performed using the Student's t test. Pearson's correlation test was used to verify the existence of a correlation between instruments' mean scores or other values.
Therefore, a series of multiple linear, logistic, and multinomial regression models (see footnotes of Tables 3, 4, 5, and 6) was used to determine the association of mean blood glucose levels with depression and anxiety symptoms assessed as continuous and categorical outcomes. The effects were adjusted for demographic, lifestyle, and clinical factors [11, 23, 38] . For logistic regression, we used the median split method to categorize the variables into binary groups. These binary groups include number of pregnancies, age at last pregnancy, and PCS. For potential confounding, the unadjusted associations of depression and anxiety symptoms with glycemic control were compared with the adjusted associations, with confounding confirmed when the unadjusted effect size and adjusted effect size estimates differed.
Results
Socio-demographic characteristics and glycemic control
The median ages of the 611 participating women at the time of this study and at diabetes diagnosis were 58 and 48 years, respectively. The majority were aged between 45 and 64 years (67 %), were married (82 %), were of Malay ethnicity (38 %), had completed only primary education (76.3 %), and were earning less than 3500 Ringgit Malaysia monthly (1 RM=3.1 US$). Regarding HbA1c levels, there were higher levels among younger women aged 35 to 44 (8.14±1.47) and 45 to 54 years (8.37±1.98) than older women (7.43±1.51). Women of Indian ethnicity had higher levels of HbA1c Anxiety and depression symptoms and glycemic control Depression (8.7 %) and anxiety (9.0 %) symptoms were not commonly reported by participants in this study. Women with anxiety had slightly higher FBG (8.54 versus 8.34) and RBG (11.10 versus 9.87) levels compared to women without anxiety symptoms. Unlike women with anxiety, women with depression symptoms had slightly higher HbA1c (8.24 versus 8.10) compared to women with no depression (Table 1) . Correlation analysis shows a weak correlation between HbA1c and anxiety (inverse) and HbA1c and depression (positive) symptoms.
The univariate analysis shows that for an increase of one category of depression symptoms, there were small increases in HbA1c (0.15 %, 95 % CI −0.38-0.68), FBG (0.33 mmol/l, 95 % CI −0.77-1.42), and RBG (1.02 mmol/l, 95 % CI −0.20-2.25). The effect estimates were reduced after adjustments for the effect of confounders (Table 2 ). In case of anxiety symptoms, HbA1c decreased by a small amount.
Very poorly controlled HbA1c was not significantly associated with increased odds of depression (OR 1.43, 95 % CI 0.45-4.55) and anxiety (OR 0.47, 95 % CI 0.15-1.49) symptoms; similarly, neither were moderately and poorly controlled HbA1c (Table 3 ). The high FBG range was not significantly associated with increased odds of anxiety (3.38, 95 % CI 0.67-17.11) and depression (1.47, 95 % CI 0.41-5.26) symptoms (Table 4) . Similarly, the expected risk remaining in the high RBG range was higher for women with anxiety and depression symptoms, but this was not significant (Table 5) .
Mental health function and glycemic control
Almost half of the participating women were found to have poor mental health functional status, as measured by MCS. On average, women with poor MCS had higher HbA1c, FBG, and RBG compared to women with good MCS (Table 1) . Correlation analysis shows a strong inverse correlation between HbA1c and MCS.
A 1-unit score increase in the MCS was associated with 0.47 % (0.17, 0.77), 0.70 mmol/l (0.10, −1.31), and 0.11 mmol/l (−0.58, 0.79) HbA1c, FBG, and RBG levels, respectively. We found very little confounding of MCS, since there was little difference between the univariate analysis coefficients and the adjusted coefficients (Table 2) . Poor MCS were significantly associated with very poorly controlled HbA1c (OR 1.93, 95 % CI 1.22-3.03) and remained significant after adjustments for confounders (OR 1.70, 95 % CI 1.01-2.88); however, neither moderately nor poorly controlled HbA1c was observed compared to women with normal level (Table 3) .
Discussion
This was the first study to investigate the association between depression, anxiety symptoms, and glycemic control among Malaysian women with T2DM. We did not find strong associations between depression and glycemic control or between anxiety and glycemic control. However, women with comorbid depression and anxiety symptoms had higher mean blood glucose values compared to those without depression and/or anxiety symptoms. In our study, fewer than 10 % of women with T2DM exhibited depression and anxiety symptoms. In contrast, almost half of the women reported poor mental functional status, as measured by MCS, indicating the opposite trend. Almost two thirds of the women (65.6 %) had HbA1c values greater than 7 % and more than a quarter of them were above 9 % indicating poor glycemic control. This reflects the trend reported by the American Diabetes Association (ADA) which suggest that only one of every two patients with diabetes has glycosylated HbA1c levels <8.0 %, and very few patients sustain HbA1c levels <7.0 % [40] .
Depression and anxiety were more common among people with poor glycemic control; however, the underlying mechanisms are not well elucidated, with some studies reporting that people with poor glycemic control are more likely to become depressed or anxious [4, 10, [13] [14] [15] [19] [20] [21] , while we found that only people with very poorly controlled glucose levels, as measured by MCS, were associated with poor mental health status. Our study found differences between people with poor glycemic control and normal glycemic level in overall mental health functioning but not specifically in mental health or vitality domains of MCS. The exact explanation for the association we observed is unclear: glycemic control may affect emotional and social function, persons with better emotional function may be more likely to be prevented from negative and positive effects of poor glycemic control, or glycemic control may be linked with other confounding variables that affect mental health function.
Our study shows that for an increase of one category of symptoms of depression, HbA1c increased, on average, by only a small amount of 0.10 %. A similar increment was reported in a longitudinal study of people with T2DM who showed, over a 4-year period, HbA1c values which were, on average, 0.13 % higher in people who had depression [12] . Previous studies have come to different conclusions about the association of depression symptoms and glycemic control; some reported a significant relationship between poorer glycemic control and depressive symptoms [14, 41] while others found an insignificant or weak association between glycemic control and depressive symptoms [18, 38, 42] . However, a meta-analysis reported a significant association [9] , and randomized clinical trials of therapies for depression demonstrated improvement in depressive symptoms corresponding with improvements in glycemic control [43, 44] , and vice versa [14] . Although our data found no significant association between anxiety and HbA1c, HbA1c values were, on average, 0.44 % lower in those with anxiety symptoms. In contrast to previous studies which suggest that anxiety disorders are associated with less favorable glycemic control among adults with DM [19] [20] [21] , our data did not show such a relationship. Interestingly, insignificant correlations of HbA1c with depression and anxiety symptoms also indicated a weak link between the two. Contrary to this, a strong inverse correlation between HbA1c and MCS was found, suggesting that women who score high on MCS scale appear to have lower HbA1c level than women who score low on MCS. A 1-unit score increase in the MCS was associated with 0.47 % (−0.17, −0.77), 0.70 mmol/l (0.10, −1.31), and 0.11 mmol/l (−0.58, 0.79) for HbA1c, FBG, and RBG levels, respectively. The adjusted effect of MCS on HbA1c was almost unchanged (reduced by only 1 %), suggesting no-or very little-confounding. Despite strong inverse correlations of MCS with DSSI and CES-D 10, only MCS reflected significant changes in glycemic control in this study. MCS might have captured the distress associated with diabetes and is reflected in the correlation between MCS and glycemic control. Fasting glucose adjusted for depression or anxiety, age, comorbidities, physical activity, BMI, physical health, and sleep problems. Classification method used was logistic and multinomial regression
Limitations
Our assessment of depression and anxiety symptoms was based on self-report of symptoms using validated instruments and not on the Diagnosis and Statistical Manual (DSM) criteria based clinical diagnostic interview. A clinical confirmation of depression or anxiety could not be done because the DSM for diagnosis of mental disorders states that the standard diagnostic criteria are applied "in the presence of a psychiatrist or trained healthcare professional." Therefore, two instruments were used to examine depression or anxiety symptoms as no clinical confirmation was available. Although we applied systematic sampling, participants who frequently attended the outpatient clinics were more likely to be sampled than those who attended less frequently, and therefore were presumed to have better glycemic control. This might have introduced selection bias.
Conclusions
This study did not find significant associations between depression and glycemic control and anxiety and glycemic control in Malaysian women with T2DM. Despite strong inverse correlations of MCS with DSSI-Anxiety and CES-D 10, only MCS tended to be associated with significant changes in glycemic control in this study. This evidence supports the hypothesis that argues against the existence of a link between depression and glycemic control and anxiety and glycemic control. However, as primary care physicians may fail to recognize a substantial number of patients with depression and/or anxiety symptoms and as the prevalence of diabetes continues to increase, in Malaysia, it is important for health care professionals managing patients with DM to be aware of the association between depression, anxiety symptoms, and glycemic control to prevent further complications.
